用于分析肠道粘膜免疫反应的免疫活性肠芯片模型
May 24th, 2024
3.1K views
我们的详细方案概述了高级肠芯片模型的创建和使用，该模型模拟具有 3D 结构和各种细胞类型的人类肠粘膜，能够深入分析响应微生物定植的免疫反应和细胞功能。
我们的研究重点是免疫活性器官芯片平台的开发和使用。通过创建这些生理相关的人源化体外模型，我们能够研究复杂的宿主-病原体相互作用。我们创造的知识可用于操纵和识别治疗传染病的分子靶点。
一个关键挑战是在体外稳态条件下与宿主组织一起维持活的微生物群。这包括复制隐窝和绒毛结构的器官型 3D 地形及其微生物定植。Intestine-on-chip 平台通过使用流动来塑造器官型结构并防止细菌过度生长来解决这个问题。
这确保了稳定的培养条件。与其他可用的肠道芯片平台相比，由于包含原代组织驻留免疫细胞，我们的模型能够详细研究人类对病原体的免疫反应。此外，模型大小支持在单个实验中进行多次读数，从而降低了总体成本和实验数量。
我们的实验室专注于使用诱导多能干细胞开发实现个性化医疗的自体系统。
概述
本文介绍了一种详细的协议，用于开发先进的芯片上肠模型，该模型模拟人类肠道黏膜。该模型包含3D结构和各种细胞类型，有助于分析与微生物定植相关的免疫反应和细胞功能。
关键研究组成部分
科学领域
- 神经科学
- 生物学
- 微生物学
背景
- 开发免疫能力的芯片上器官平台。
- 研究宿主-病原体相互作用的重要性。
- 体外维持活性微生物群的挑战。
- 复制器官型3D结构的需求。
研究目的
- 创建生理学上相关的人源化体外模型。
- 分析对微生物定植的免疫反应。
- 识别感染性疾病治疗的分子靶点。
使用的方法
- 创建芯片上肠平台。
- 使用流动来塑造器官型结构。
- 维持微生物群的稳态条件。
- 深入分析细胞功能。
主要结果
- 成功模拟人类肠道黏膜。
- 增强对免疫反应的理解。
- 洞察微生物定植的效果。
- 在治疗靶点识别方面的潜在应用。
结论
- 芯片上肠模型是研究的宝贵工具。
- 它允许在受控环境中研究复杂的相互作用。
- 未来的研究可以利用该模型进行感染性疾病研究。
常见问题
什么是芯片上肠模型？
芯片上肠模型使用3D结构和各种细胞类型模拟人类肠道黏膜。
该模型如何帮助研究免疫反应？
它允许在受控环境中对微生物定植的免疫反应进行深入分析。
体外维持微生物群的主要挑战是什么？
主要挑战包括复制器官型结构和防止细菌过度生长。
这项研究的潜在应用是什么？
该研究可以帮助识别感染性疾病治疗的分子靶点。
流动如何为模型的有效性做出贡献？
流动塑造器官型结构并维持微生物群的稳态条件。
这个模型可以用于其他类型的研究吗？
是的，它可以适应与肠道健康和疾病相关的各种研究。
Executive Industry Relevance
The immunocompetent intestine-on-chip model enables high-fidelity analysis of gut mucosal immune responses under physiologically relevant conditions, addressing a critical gap in preclinical discovery. By integrating primary human immune cells and supporting complex host-microbiota interactions, this platform enhances predictive confidence for target validation and mechanistic de-risking in infectious and inflammatory disease pipelines. Its multiplexed functional readouts and compatibility with advanced imaging position it as a reusable asset for translational research and portfolio triage.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of therapeutic hypotheses involving gut mucosal immunity and host-pathogen interactions.
- Supports biological de-risking by modeling tissue-resident immune cell responses to microbial colonization.
- Facilitates functional target validation through quantitative readouts such as cytokine release and immune cell infiltration.
- Improves predictive confidence for advancing targets implicated in intestinal barrier function and immune modulation.
Screening & Assay Development
- Provides a validated, organotypic system for standardized assessment of compound effects on epithelial integrity and immune activation.
- Delivers reproducible, multiplexed outputs including permeation assays and immunofluorescence-based cell differentiation metrics.
- Enables scalable screening of candidate molecules or biologics in a physiologically relevant microenvironment.
- Supports reliable evaluation of interventions targeting host-microbiota or immune pathways.
Translational & Preclinical Research
- Aligns with disease-relevant mechanisms by modeling human mucosal immune responses to bacterial and fungal challenges.
- Bridges discovery and preclinical validation through continuity of functional and structural readouts.
- Facilitates risk-adjusted advancement decisions for assets targeting gut immune homeostasis or infection.
- Provides mechanistic insights supporting translational biomarker development.
Pipeline & Workflow Integration
This intestine-on-chip model fits from early discovery through lead identification and preclinical mechanistic studies, supporting iterative hypothesis testing and target prioritization.
- Discovery Biology: Enables robust null hypothesis testing of immune response pathways and barrier function under controlled microbial exposure.
- Screening: Delivers quantitative, reproducible outputs for compound triage and assay standardization.
- Analytics: Supports multiplexed measurements including cytokine profiling, immune cell infiltration, and epithelial integrity.
- Translational Research: Provides a platform for aligning in vitro findings with disease-relevant biomarkers and preclinical endpoints.
- Enterprise Reuse: Functions as a modular, scalable system adaptable to diverse gut-related R&D programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in gut immune target validation.
- Operational Value: Standardizes complex co-culture workflows and enables reproducible, multiplexed data generation.
- Strategic Value: Improves go/no-go decision quality and capital efficiency by reducing late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of assets targeting intestinal immunity or infection.
Implementation Considerations
- Requires expertise in microfluidic biochip handling and advanced cell culture techniques.
- Demands access to immunofluorescence imaging and multiplexed analytical infrastructure.
- Necessitates cross-team standardization for reproducibility and data comparability.
- Adaptation across different immune cell sources or microbial species may require protocol optimization.
- Model complexity and maintenance of homeostatic microbiota present practical limitations for high-throughput use.
Biopharma FAQs
Why does null hypothesis testing of cytokine release matter for target validation?
Null hypothesis testing of cytokine release in this intestine-on-chip model enables objective assessment of immune activation in response to microbial stimuli, supporting rigorous target validation. This quantitative approach reduces bias and increases confidence in mechanistic findings relevant to gut mucosal immunity. It informs go/no-go decisions for advancing immune-modulating candidates.
How does isolation of immune cell infiltration outputs fit the discovery pipeline?
Isolating immune cell infiltration as a dependent variable allows teams to dissect specific host-pathogen interactions and evaluate intervention effects early in discovery. This supports mechanistic de-risking and prioritization of targets with direct impact on mucosal immune responses. It streamlines the transition from hypothesis generation to functional validation.
What do quantitative measurements of epithelial barrier permeation enable?
Quantitative permeation assays provide actionable data on barrier integrity and compound effects, enabling direct comparison across experimental conditions. These measurements support screening, assay development, and mechanistic studies by linking molecular interventions to functional outcomes. They enhance predictive value for downstream translational research.
Why are replication requirements for immune response assays critical for cross-functional collaboration?
Replication of immune response assays ensures data reliability and comparability across teams, facilitating cross-functional decision-making. Standardized protocols and reproducible outputs are essential for integrating findings into broader R&D workflows and supporting regulatory or translational milestones. This alignment accelerates portfolio progression and reduces risk.
What statistical analysis capabilities are required before implementing multiplexed readouts?
Robust statistical analysis is necessary to interpret multiplexed outputs such as cytokine profiles, immune cell infiltration, and barrier function. Teams must establish thresholds for significance, control for variability, and validate analytical pipelines to ensure data integrity. These capabilities underpin confident advancement of discovery-stage assets.
